Positron emission tomography to quantify brain nicotine abstinence by Domino, E. F. & Tsukada, H.
LB-3
POSITRON EMISSION TOMOGRAPHY TO QUANTIFY
BRAIN NICOTINE ABSTINENCE. E. F. Domino, MD, H.
Tsukada, PhD, University of Michigan, Hamamatsu Photonics K.K.,
Japan, Ann Arbor, MI.
BACKGROUND: The hypothesis for this research was that brain
dopamine (DA) utilization would decrease during abstinence from
repeated nicotine administration.
METHODS: Six young Macaca mulatta monkeys were given
0.9% NaCl or nicotine in doses of 32 or 100 g/kg i.m. bid for 9 days.
On the 10th day, PET measurements were repeated before and after
nicotine. The PET studies were done in habituated, trained, and fully
conscious animals.
RESULTS: Compared to the control condition, the binding po-
tential (k3/k4) of [11C]raclopride in dorsal or ventral striatum did not
change with either dose following acute repeated nicotine, or in the
nicotine abstinent state. Compared to control, acute nicotine in either
dose did not affect the DA utilization rate constant (k3) in dorsal or
ventral striatum as measured by [Beta-11C]L-DOPA. However, in
monkeys given nicotine repeatedly, after overnight nicotine absti-
nence, DA utilization was reduced significantly. A subsequent nico-
tine dose increased DA utilization to slightly above control levels.
The ventral striatum showed greater changes than the dorsal striatum.
CONCLUSIONS: The reduced rate of DA synthesis as assayed
with [Beta-11C]L-DOPA during nicotine abstinence and its reversal
by nicotine provides an important PET measure of brain nicotine
dependence and withdrawal.
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REDUCTION OF HALOPERIDOL-INDUCED SIDE EFFECTS
BY ACP-103 IN HEALTHY VOLUNTEERS. A. E. Grahnen, PhD,
K. E. Vanover, PhD, D. M. Weiner, PhD, L. Nilsson, MD, B. Tolf,
PhD, U. Hacksell, PhD, M. R. Davis, PhD, Quintiles Nordic Region,
ACADIA Pharmaceuticals, Uppsala, Sweden.
BACKGROUND/AIMS: A novel serotonin 2A (5-HT2A) recep-
tor inverse agonist, ACP-103, was tested to determine the potential of
ACP-103 to inhibit central nervous system side effects produced by
haloperidol.
METHODS: Healthy male volunteers participated in a random-
ized, double blind, placebo-controlled, single dose crossover study.
All subjects received a single dose of haloperidol (7.5 mg) in com-
bination with either a single dose of placebo or a single dose of
ACP-103 (100 mg). The washout period between treatment combi-
nations was two weeks.
RESULTS: Haloperidol caused measurable akathisia in 13 of 18
subjects and induced approximately a 3-fold increase in prolactin
secretion. ACP-103 treatment caused a measurable and temporally
consistent decrease in haloperidol-induced akathisia compared to
placebo treated subjects as measured by the Barnes Akathisia Scale.
ACP-103 significantly reduced haloperidol-induced hyperprolactine-
mia.The pharmacokinetics of haloperidol and ACP-103 were not
affected by their co-administration. No serious adverse events were
reported.
CONCLUSIONS: Data suggest that ACP-103, when co-
administered with existing antipsychotic drugs, may reduce their side
effects and expand their range of efficacy. ACP-103 is being devel-
oped as an adjunctive therapy for schizophrenia and as a therapy for
treatment-induced dysfunction in Parkinson’s disease.
LB-5
AN OPEN-LABEL CLINICAL EVALUATION OF TIGECY-
CLINE (TGC) CONCENTRATIONS IN SELECTED TISSUES
AND FLUIDS. M. H. Gotfried, MD, K. A. Rodvold, PharmD, M.
Cwik, PhD, S. M. Troy, MS, G. Dukart, MD, E. J. Ellis-Grosse, PhD,
Pulmonary Associates, P. A.; College of Medicine, University of
Arizona, College of Pharmacy and Medicine, University of Illinois at
Chicago, IIT Research Institute, Life Sciences Operation, Wyeth
Research, Phoenix, AZ.
BACKGROUND/AIMS: TGC, an expanded spectrum glycylcy-
cline in development for the treatment of skin and skin structure
infections and intraabdominal infections, has a large volume of
distribution (Vss600 L). TGC concentrations were measured in
serum, lung, colon, gallbladder, bone, bile, and synovial fluid.
METHODS: Serum TGC was determined (by LC/MS/MS) pre-
dose, at end of 30-minute infusion of the single 100-mg TGC dose,
and at tissue collection (during scheduled elective surgery).
RESULTS: At the time of this analysis, data from 54 subjects (of
120 planned) were available. Serum samples from 52 and tissue/fluid
samples from 49 subjects were analyzed. Median TGC serum con-
centrations were 1425 ng/mL, 198 ng/mL, and 60 ng/mL at end of
infusion, 4 hours, and 24 hours, respectively. Gallbladder, lung, and
colon had the highest TGC concentrations; synovial fluid and bone
had the lowest. One (1) death, the only serious adverse event (AE),
occurred after the study; it was not related to TGC. Treatment-related
AEs of nausea (23, 43%) and vomiting (7, 13%) were most frequently
reported. No subject withdrew because of AEs.
CONCLUSIONS: Based on this analysis, a 100-mg TGC dose
distributes into gallbladder, lung, and colon at or above MICs shown
by in vitro data to be efficacious, and into bone tissue and synovial
fluid. In animal studies, labeled TGC achieved high concentrations in
bone. Tight TGC-bone binding, with poor extraction for assay, may
have occurred in this study, rather than low bone uptake. The study
is ongoing.
Concentration MeanSD tissue/serum ratios
Range (ng/g) 4 hrs 8 hrs 12 hrs 24 hrs
Gallbladder
(n17)
238-20,700 3940 1519 8579 3842
Lung (n2) 653-1890 8.6a NA NA 14.6a
Colon (n11) 87-995 2.11.9 1.72.3 2.12.5 NA
Bone (n19) BQL-269 0.350.16 NA 1.101.25 NA
Synovial fluid
(n15)
26-181 0.580.24 NA 0.890.49 0.710.15
a: 1 subject at each time point; NAdata not available; BQLbelow
quantitation limit.
CLINICAL PHARMACOLOGY & THERAPEUTICS
P98 American Society for Clinical Pharmacology and Therapeutics FEBRUARY 2005
